MEDICLIN Aktiengesellschaft reported consolidated group sales of EUR 586.9 million in the first nine months of 2025, representing a 5.1% increase compared to the same period last year. The group operating result showed substantial improvement, reaching EUR 48.9 million compared to EUR 34.5 million in the first nine months of 2024, marking a 41.7% increase. Overall capacity utilization within the Group remained stable at 86.8%, slightly above the previous year's level of 86.0%.
The post-acute segment demonstrated particularly strong performance with sales increasing by 9.3% to EUR 394.6 million. Segment operating result in this division rose by EUR 9.6 million to EUR 47.6 million, while the cost of materials ratio improved by 0.9 percentage points to 19.5%. Personnel expenses in the post-acute segment increased by 9.4% to EUR 205.0 million, primarily due to salary increases and higher employee numbers, though the personnel expense ratio remained unchanged at 51.9%.
Developments in the acute segment were significantly influenced by the sale of the former MEDICLIN Herzzentrum Coswig. Despite a 3.2% decrease in segment sales, the operating result improved dramatically by 117.2% to EUR 0.7 million, recovering from a loss of EUR 3.8 million in the same period last year. The cost of materials in this segment fell by 4.8% to EUR 47.6 million, while personnel expenses decreased by 4.8% to EUR 101.0 million.
The nursing care segment reported sales of EUR 18.6 million but experienced a decline in operating result to EUR -0.4 million, down EUR 0.5 million from the previous year. Meanwhile, the service segment showed positive development with sales increasing to EUR 74.8 million and operating result improving by EUR 0.8 million to EUR 1.0 million.
The Management Board confirmed its guidance for the 2025 financial year, expecting consolidated group sales growth between 2.0% and 5.0% and consolidated group EBIT between EUR 53.0 million and EUR 64.0 million. Tino Fritz, CFO of MEDICLIN, commented that the company continues to assess business development as solid despite current conditions and typical seasonal effects in the fourth quarter. The interim report as of 30 September 2025 is available at https://www.mediclin.de in both German and English versions.
This financial performance is significant for healthcare stakeholders as it demonstrates MEDICLIN's ability to maintain stable operations while improving profitability across most segments. The consistent capacity utilization rate of 86.8% indicates efficient resource management in a sector often challenged by fluctuating patient volumes. The substantial improvement in the acute segment's operating result, turning from loss to profit, suggests effective strategic restructuring following facility sales. For investors and industry observers, these results provide confidence in the healthcare provider's operational stability and strategic direction during a period of economic uncertainty in the European healthcare landscape.
